Timpel Medical Corp

Timpel Medical develops and markets the ENLIGHT 2100, a bedside electrical impedance tomography (EIT) system for real-time, non-invasive ventilation monitoring and precision mechanical ventilation guidance. The system uses high-frequency, low-intensity electrical signals transmitted through electrodes embedded in a chest strap to generate live dynamic images of lung ventilation and perfusion (V/Q) distribution without radiation or patient transport. Core applications include ICU ventilator management, neonatal and pediatric respiratory support, PEEP titration, detection of ventilator asynchrony, and weaning protocols from intubation to extubation. The ENLIGHT 2100 integrates clinical decision-support tools: Ventilation Screen, PEEP Titration, Trends Screen, Asynchrony Tool, V/Q Tool, and Neonatal Monitoring. The system operates bedside, is operator-independent, and suitable for adult, pediatric, and neonatal patients. Timpel is privately held and backed by FinHealth (Brazilian private equity/venture capital), FAPESP, and FINEP (Brazilian public research funding agencies). The company maintains offices in the Netherlands (Eindhoven), Brazil (São Paulo), and the USA (San Diego). Timpel emphasizes precision medicine, heterogeneous lung physiology adaptation, objective-driven ventilation strategies, and early detection of pulmonary complications before clinical manifestation.